CASCINU, Stefano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 26.457
AS - Asia 9.553
EU - Europa 9.274
SA - Sud America 1.408
Continente sconosciuto - Info sul continente non disponibili 373
AF - Africa 269
OC - Oceania 34
Totale 47.368
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 26.025
SG - Singapore 2.840
GB - Regno Unito 2.663
CN - Cina 1.912
IT - Italia 1.722
HK - Hong Kong 1.294
VN - Vietnam 1.184
BR - Brasile 1.075
DE - Germania 827
FI - Finlandia 738
BD - Bangladesh 721
SE - Svezia 691
IE - Irlanda 441
UA - Ucraina 433
FR - Francia 403
RU - Federazione Russa 369
PL - Polonia 368
TR - Turchia 365
IN - India 254
CA - Canada 239
ID - Indonesia 202
BG - Bulgaria 190
JP - Giappone 115
IQ - Iraq 102
AR - Argentina 101
KR - Corea 93
MX - Messico 80
ES - Italia 61
EG - Egitto 59
EC - Ecuador 57
NL - Olanda 57
PK - Pakistan 53
ZA - Sudafrica 50
MY - Malesia 49
VE - Venezuela 48
BE - Belgio 45
LT - Lituania 43
CO - Colombia 41
AE - Emirati Arabi Uniti 40
MA - Marocco 40
PH - Filippine 36
AT - Austria 33
CL - Cile 32
NP - Nepal 32
TW - Taiwan 31
UZ - Uzbekistan 31
SA - Arabia Saudita 26
TN - Tunisia 26
AU - Australia 25
CZ - Repubblica Ceca 25
JO - Giordania 25
KE - Kenya 23
RO - Romania 22
JM - Giamaica 21
CH - Svizzera 20
PY - Paraguay 20
DZ - Algeria 19
IR - Iran 18
CR - Costa Rica 17
EU - Europa 17
TH - Thailandia 17
MD - Moldavia 16
DO - Repubblica Dominicana 15
PT - Portogallo 15
AZ - Azerbaigian 14
HU - Ungheria 14
IL - Israele 13
PE - Perù 13
UY - Uruguay 13
NO - Norvegia 11
SN - Senegal 11
OM - Oman 10
HN - Honduras 9
TT - Trinidad e Tobago 9
AL - Albania 8
KZ - Kazakistan 8
SV - El Salvador 8
SY - Repubblica araba siriana 8
BH - Bahrain 7
ET - Etiopia 7
NZ - Nuova Zelanda 7
PA - Panama 7
RS - Serbia 7
BO - Bolivia 6
DK - Danimarca 6
GH - Ghana 6
GT - Guatemala 6
HR - Croazia 6
LB - Libano 6
QA - Qatar 6
SK - Slovacchia (Repubblica Slovacca) 6
AO - Angola 5
CY - Cipro 5
GE - Georgia 5
GR - Grecia 5
MN - Mongolia 5
MT - Malta 5
NI - Nicaragua 5
PS - Palestinian Territory 5
A2 - ???statistics.table.value.countryCode.A2??? 4
Totale 46.928
Salva come PNG Salva come JPEG
Città #
Fairfield 3.220
Ashburn 2.617
Santa Clara 1.966
Singapore 1.814
Woodbridge 1.805
Southend 1.676
Houston 1.471
Seattle 1.272
Hong Kong 1.269
Chandler 1.184
Cambridge 1.023
Wilmington 1.013
San Jose 775
Jacksonville 749
Dearborn 736
Ann Arbor 731
Council Bluffs 615
Helsinki 599
Beijing 554
London 489
Nyköping 468
Dublin 434
Warsaw 355
Modena 318
Ho Chi Minh City 310
New York 305
The Dalles 291
Los Angeles 283
Dallas 267
Hanoi 267
San Diego 244
Izmir 219
Chicago 214
Princeton 186
Sofia 186
Columbus 185
Lauterbourg 181
Eugene 174
Milan 172
Jakarta 158
Boardman 150
Buffalo 146
Hefei 132
Shanghai 116
Moscow 114
Dong Ket 103
São Paulo 92
Tokyo 84
Seoul 83
Falls Church 82
Munich 77
Frankfurt am Main 74
Orem 73
Phoenix 69
Salt Lake City 65
Bremen 63
Da Nang 63
Fremont 63
Rome 57
Redwood City 55
Ottawa 54
Baghdad 53
Atlanta 50
Bologna 48
Guangzhou 46
Toronto 46
Redondo Beach 39
Brooklyn 38
Mumbai 38
Brussels 37
Miano 36
San Giuliano Milanese 36
Belo Horizonte 34
Chennai 32
Haiphong 32
Tampa 32
Denver 31
Naples 31
Rio de Janeiro 31
Des Moines 30
Poplar 30
Norwalk 29
Tashkent 29
Cairo 28
Montreal 27
Turku 25
Brasília 24
Mexico City 24
Miami 24
Florence 23
Nuremberg 23
Dhaka 22
Lawrence 22
Asyut 21
Detroit 21
Düsseldorf 21
Falkenstein 21
Nanjing 21
Paris 21
Johannesburg 20
Totale 33.806
Salva come PNG Salva come JPEG
Nome #
Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients. 638
Adjuvant chemotherapy in colon cancer: can we improve quality of care? 594
Endocrine sensitive metastatic breast cancer and bone only disease: are the new treatments always better? 466
A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study) 450
GD2 expression in breast cancer. 433
Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer 432
ERBB2 mutations in hormone receptor positive primary breast cancers samples and in their matched endocrine-resistant recurrences. 430
Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going 409
Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. 402
Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients 401
Clinical and molecular analysis of long-term HER2 positive metastatic breast cancer survivors. 378
Hereditary pancreatic cancer: A retrospective single-center study of 5143 Italian families with history of BRCA-related malignancies 375
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus 368
M09Quantification of circulating cell-free DNA by fluorimetry (Qubit) and spectrophotometry (NanoDrop) in patients with malignant melanoma and prostate cancer 367
The evolving role of microsatellite instability in colorectal cancer: A review 362
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? 361
Impact of body composition parameters on tumor response to neoadjuvant chemotherapy in operable breast cancer patients. 361
BRAF ,NRASandC-KITAdvanced Melanoma: Clinico-pathological Features, Targeted-Therapy Strategies and Survival 360
Quality of life and anxious-depressive symptoms in cancer patients undergoing mindfulness-based interventions: Feasibility and preliminary outcomes on prospective single-centre case-control study (MIND4ME St.) 358
First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis 357
Endocrine-based targeted combination versus endocrine therapy alone as first-line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials. 356
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. 354
Primary and secondary prevention to effectively reduce the risk of bisphosphonate-related osteonecrosis of the jaw in patients with bone metastases . 352
Atrial fibrillation in patients with active malignancy and use of anticoagulants: Under-prescription but no adverse impact on all-cause mortality 339
Predictive role of haemoglobin on disease response to neoadjuvant chemotherapy in breast cancer. 337
Post-surgical pyoderma gangrenosum of the breast: needs for early diagnosis and right therapy. 337
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 329
Role of evaluating tumor‑infiltrating lymphocytes, programmed death‑1 ligand 1 and mismatch repair proteins expression in malignant mesothelioma 328
Metronomic Capecitabine Effectively Blocks Leptomeningeal Carcinomatosis From Breast Cancer: A Case Report and Literature Review. 322
5-Fluorouracil pharmacogenomics: still rocking after all these years? 321
Safety and efficacy of T-DM1 in HER2 positive metastatic breast cancer patients: a real word experience. 321
Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients 321
Transient sunitinib resistance in gastrointestinal stromal tumors. 319
Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue 318
Molecular profile in primary and metastatic breast cancer treated with Exemestane and Everolimus. 318
Il trattamento di prima e seconda linea nel carcinoma gastrico 318
Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier) 317
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol 317
A randomized, double-blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel 316
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status 313
9 Weeks vs 1 Year Adjuvant Trastuzumab in Combination with Chemotherapy: Preliminary Cardiac Safety Data of the Phase III Multicentric Italian Study Short-HER. 311
Androgen receptor expression in early triple-negative breast cancer: clinical significance and prognostic associations. 309
Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid. 306
Combined Hormonal Contraceptive Use and Risk of Breast Cancer in a Population of Women With a Family History 305
Novel Agents, Combinations and Sequences for the Treatment of Advanced Renal Cell Carcinoma: When is the Revolution Coming? 304
[11C]-Methionine Positron Emission Tomography in the Postoperative Imaging and Followup of Patients with Primary and Recurrent Gliomas 295
Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. 295
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial 293
Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat? 293
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale 290
Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2 A meta-analysis of published trials 288
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib 285
ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib 284
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer 284
A novel approach to manage skin toxicity caused by therapeutic agents targeting epidermal growth factor receptor. 280
Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New 279
PREVALENCE OF NODE NEGATIVE AND SMALL SIZE TUMORS IN A NATIONAL, RANDOMISED, PHASE III ADJUVANT TRIAL IN HER2 + EARLY BREAST CANCER (SHORT-HER STUDY) 278
Impact of anaemia on tumor response to neoadjuvant chemotherapy in breast cancer patients . 276
Breast ultrasonography (BU) in the screening protocol for women at hereditary-familial risk of breast cancer: has the time come to rethink the role of BU according to different risk categories? 275
eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: Final results of the ePHAS study 275
A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer 274
Quantification of circulating cell-free DNA by fluorimetry (Qubit) and spectrophotometry (NanoDrop) in patients with malignant melanoma and prostate cancer 272
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status. 272
The Italian Rare Pancreatic Exocrine Cancer Initiative 270
Randomized trial of low-dose morphine versus weak opioids in moderate cancer pain 269
A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors 266
Class 1, 2, and 3 BRAF-mutated metastatic colorectal cancer: A detailed clinical, pathologic, and molecular characterization 266
Gastrointestinal neuroendocrine tumors: Searching the optimal treatment strategy-A literature review 263
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 262
Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab. 261
Immune-inflammatory and clinicopathologic prognostic factors in a Western cohort of resected gastric cancers (GCs) 259
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study 257
Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. 256
Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials 255
The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation 254
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 253
Multimodal treatment of resectable pancreatic ductal adenocarcinoma 253
Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in patients with clear cell renal cell carcinoma 250
Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: A systematic review and meta-analysis of clinical trials 249
Correlation of Stomatitis and Cutaneous Toxicity With Clinical Outcome in Patients With Metastatic Renal-Cell Carcinoma Treated With Everolimus 249
Allele polymorphisms of tumor integrins correlate with peritoneal carcinosis capability of gastric cancer cells in radically resected patients. 249
Multicentric prospective study of validation of angiogenesis polymorphisms in HCC patients treated with sorafenib. INNOVATE study 248
The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer 248
Bone metastases- Pharmacological treatment 245
Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. 244
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: A retrospective study 244
A user-friendly nomogram to predict relapse-free survival (RFS) in western patients with resected gastric cancer (GC) 244
FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study. 243
Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma 243
State of the art for cardiotoxicity due to chemotherapy and to targeted therapies: a literature review. 242
Cancer stem cell gene profile as predictor of relapse in high risk stage II and stage III, radically resected colon cancer patients. 241
Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial. 241
Immunohistochemical mismatch repair proteins expression as a tool to predict the melanoma immunotherapy response 241
BRCA mutations among triple negative breast cancer without family history of breast and ovarian cancer: The Modena family cancer clinic experience 241
BRAF-mutated colorectal cancer: Clinical and molecular insights 239
Thymic neoplasms: an update on the use of chemotherapy and new targeted therapies. A literature review. 238
Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy 238
Gastro-entero-pancreatic neuroendocrine tumors: Is now time for a new approach? 238
Pre and post anti Her-2 therapy era: a mono-institutional analysis of the outcome in patients with residual disease after neoadjuvant therapy for Her-2 positive locally advanced breast cancer. 238
Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients. 236
Totale 30.711
Salva come PNG Salva come JPEG
Categoria #
all - tutte 176.522
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 176.522
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.861 0 0 327 152 96 237 184 191 373 348 642 311
2022/20233.538 411 357 221 315 409 418 51 283 766 41 148 118
2023/20242.030 76 115 115 190 417 121 250 346 43 53 95 209
2024/20256.810 273 93 122 455 1.438 1.039 487 457 825 394 413 814
2025/202613.065 678 270 874 1.092 1.539 1.360 1.859 701 1.269 1.139 1.260 1.024
2026/20271.563 530 986 47 0 0 0 0 0 0 0 0 0
Totale 47.368